Our Partners
GeminiVax is built around a specialised technology and development network combining vector vaccine engineering, epitope-guided antigen design, immune-response modulation, animal-health vaccine development and target-species research expertise.
Our partners and affiliated technology companies provide key components of the GeminiVax development model: influenza-vector technology, bioinformatics-supported antigen selection, immunomodulating peptide technologies, veterinary vaccine strategy, and access to scientific and clinical expertise required for advancing vaccine candidates toward target-animal evaluation, field studies and commercial partnership.
Capricorn Technologies GmbH
Core technology partner providing the influenza-vector platform that forms the basis of GeminiVax vaccine-candidate development. Capricorn’s experience in attenuated influenza-vector vaccines provides the scientific and technical foundation for GeminiVax’s swine vaccine programmes.
Aptum Biologics Ltd.
Technology and bioinformatics partner supporting rational antigen and epitope selection. Aptum’s tools and expertise contribute to the design of compact antigenic cassettes incorporating selected CTL, T-helper and B-cell epitopes.
Partnering Opportunities
GeminiVax is open to strategic partnerships with animal-health companies, vaccine manufacturers, swine-production groups, research institutions and public-sector organisations. Partnerships may include vaccine co-development, target-animal studies, field evaluation, licensing, regional commercialisation or grant-supported development programmes.